Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. The Company launched Oxtellar XR and Trokendi XR, two novel neurology products for the treatment of epilepsy.  Supernus Pharmaceuticals is also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder and its coexisting disorders, and depression.

Type
Public
HQ
Rockville, US
Founded
2005
Size (employees)
363 (est)
Supernus Pharmaceuticals was founded in 2005 and is headquartered in Rockville, US
Report incorrect company information

Key People/Management at Supernus Pharmaceuticals

Jack Khattar

Jack Khattar

President and CEO

Supernus Pharmaceuticals Office Locations

Supernus Pharmaceuticals has an office in Rockville
Rockville, US (HQ)
1550 E Gude Dr
Show all (1)
Report incorrect company information

Supernus Pharmaceuticals Financials and Metrics

Supernus Pharmaceuticals Financials

Supernus Pharmaceuticals's revenue was reported to be $215 m in FY, 2016 which is a 48.9% increase from the previous period.
USD

Revenue (Q1, 2018)

90.4 m

Gross profit (Q1, 2018)

87.2 m

Gross profit margin (Q1, 2018), %

96.4%

Net income (Q1, 2018)

26.4 m

EBIT (Q1, 2018)

31.4 m

Market capitalization (25-May-2018)

3 b

Closing share price (25-May-2018)

57.3

Cash (31-Mar-2018)

444.1 m
Supernus Pharmaceuticals's current market capitalization is $3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

12 m122 m144.4 m215 m

Revenue growth, %

915%18%49%

Cost of goods sold

1.1 m5.8 m8.4 m12 m

Gross profit

10.9 m116.3 m136 m203 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

1.3 m9.1 m29.7 m52.5 m28.1 m35.1 m38.6 m43.1 m50.4 m56.8 m57.6 m75.8 m90.4 m

Cost of goods sold

33 k494 k1.7 m1.3 m1.6 m1.8 m2.2 m2 m2.8 m3.4 m2.9 m3.9 m3.3 m

Gross profit

1.2 m8.6 m28 m51.2 m26.5 m33.3 m36.3 m41 m47.7 m53.4 m54.6 m72 m87.2 m

Gross profit Margin, %

97%95%94%97%94%95%94%95%95%94%95%95%96%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

33 m36.4 m34.2 m66.4 m

Accounts Receivable

5.1 m17.3 m25.9 m41.5 m

Inventories

7.2 m3.8 m5.3 m16.8 m

Current Assets

97.2 m108.9 m106 m151.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

22.9 m12.3 m12 m37.8 m25.8 m33.1 m26.3 m19.8 m36.2 m54.3 m59.6 m61.7 m444.1 m

Accounts Receivable

7.2 m9.7 m10.9 m15.3 m19.3 m17.9 m23.6 m30.7 m34.3 m36.2 m38.9 m51.2 m67.9 m

Inventories

5.2 m8 m10.1 m11.1 m13.7 m13.6 m14.7 m13 m16.4 m17.5 m19.2 m16.6 m19.1 m

Current Assets

102.9 m79.9 m72 m103 m101.5 m105.7 m102.6 m94 m114.1 m138.2 m149.8 m165.5 m583.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(92.3 m)19.9 m14 m91.2 m

Depreciation and Amortization

742 k928 k921 k2.4 m

Inventories

(6 m)(6.3 m)854 k(4.2 m)

Accounts Payable

8.5 m(1.3 m)2.1 m3.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(69.9 m)(15.5 m)(12.3 m)15.5 m917 k2.9 m7.1 m5 m15 m76.9 m10.3 m27.7 m26.4 m

Depreciation and Amortization

526 k227 k460 k701 k214 k431 k651 k429 k1.1 m1.7 m741 k2.1 m1.7 m

Inventories

(4 m)(805 k)(2.9 m)(4 m)(261 k)(151 k)(1.3 m)(457 k)(3.8 m)(4.9 m)(2.4 m)178 k(2.8 m)

Accounts Payable

4.3 m(3.7 m)730 k3.7 m(1 m)2.7 m949 k(1.7 m)(2.1 m)(1.6 m)(3.1 m)50 k(3.4 m)
USDY, 2018

Financial Leverage

2.3 x
Show all financial metrics
Report incorrect company information

Supernus Pharmaceuticals News and Updates

Report incorrect company information